|
YTD 2020
|
Q3 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER1
|
Actual
|
CER
|
|||
Total Revenue
|
19,207
|
8
|
10
|
6,578
|
3
|
3
|
- Product
Sales
|
18,879
|
9
|
11
|
6,520
|
6
|
7
|
- Collaboration
Revenue
|
328
|
(19)
|
(18)
|
58
|
(79)
|
(78)
|
|
|
|
|
|
|
|
Reported2
EPS3
|
$1.66
|
n/m4
|
n/m
|
$0.49
|
n/m
|
n/m
|
Core5
EPS
|
$2.95
|
13
|
16
|
$0.94
|
(4)
|
-
|
|
YTD 2020
|
Q3 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Tagrisso: Product
Sales
|
3,171
|
38
|
39
|
1,155
|
30
|
30
|
Imfinzi: Product
Sales
|
1,487
|
42
|
43
|
533
|
29
|
29
|
Lynparza: Product
Sales
|
1,280
|
51
|
53
|
464
|
42
|
42
|
Lynparza: Collaboration
Revenue
|
135
|
(48)
|
(48)
|
-
|
n/m
|
n/m
|
Calquence: Product Sales
|
340
|
n/m
|
n/m
|
145
|
n/m
|
n/m
|
Enhertu: Collaboration
Revenue
|
63
|
n/m
|
n/m
|
27
|
n/m
|
n/m
|
|
YTD 2020
|
Q3 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Farxiga: Product
Sales
|
1,373
|
22
|
26
|
525
|
32
|
35
|
Brilinta: Product
Sales
|
1,230
|
7
|
9
|
385
|
(7)
|
(7)
|
Bydureon: Product
Sales
|
326
|
(21)
|
(20)
|
110
|
(14)
|
(14)
|
Lokelma: Product
Sales
|
48
|
n/m
|
n/m
|
21
|
n/m
|
n/m
|
Roxadustat: Collaboration Revenue
|
19
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
|
YTD 2020
|
Q3 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Symbicort: Product
Sales
|
2,042
|
15
|
16
|
599
|
(2)
|
(2)
|
Fasenra: Product
Sales
|
666
|
34
|
34
|
240
|
19
|
18
|
Pulmicort: Product
Sales
|
628
|
(40)
|
(39)
|
151
|
(55)
|
(55)
|
Regulatory
approvals
|
- Imfinzi - ES-SCLC1 (EU, JP)
- Enhertu - gastric cancer (3rd line,
HER2+2) (JP)
|
Regulatory
submission acceptances and/or submissions
|
- Imfinzi - new, once every four weeks
(Q4W) dosing (US; Priority Review, EU; accelerated
assessment)
- Imfinzi - ES-SCLC (CN)
- Enhertu - gastric cancer (3rd line,
HER2+) (US; Priority Review)
- Brilinta - stroke (THALES)
(CN)
- Symbicort - mild asthma
(EU)
- anifrolumab - lupus
(SLE7) (US, EU)
|
Major
Phase III data readouts or other significant
developments
|
- Tagrisso - adjuvant NSCLC (EGFRm):
Breakthrough Therapy Designation8 (US)
- Lynparza - ovarian cancer (1st line,
HRD+) (PAOLA-1): positive opinion (EU)
- Lynparza - prostate cancer (2nd line,
BRCAm9): positive opinion (EU)
- Forxiga - HF10 CVOT: positive opinion
(EU)
- Farxiga - CKD11: Breakthrough Therapy Designation
(US)
- Fasenra - nasal polyps12: Phase III primary endpoints
met
- Trixeo - COPD13: positive opinion (EU)
|
Timing
|
News
flow
|
Q4 2020
|
- Tagrisso - adjuvant NSCLC (EGFRm):
regulatory submission (EU)
- Imfinzi - new Q4W dosing: regulatory
decision (US)
- Lynparza - ovarian cancer (1st line)
(PAOLA-1): regulatory decision (EU, JP)
- Lynparza - breast cancer (BRCAm):
regulatory decision (CN)
- Lynparza - prostate cancer (2nd line,
BRCAm): regulatory decision (EU)
- Enhertu - breast cancer (3rd line,
HER2+): regulatory decision (EU)
- Calquence - CLL14: regulatory decision (EU)
- Forxiga - HF CVOT: regulatory decision
(EU, JP)
- Farxiga - CKD: regulatory
submission
- Brilinta - stroke (THALES): regulatory
decision (US)
- roxadustat -
anaemia in CKD: regulatory decision (US)
- Symbicort - mild asthma: regulatory
decision (CN)
- Trixeo - COPD: regulatory decision
(EU)
- tezepelumab -
severe asthma: data readout
- anifrolumab - lupus
(SLE): regulatory submission (JP)
- AZD1222 -
SARS-CoV-2: data readout, regulatory submission
|
H1 2021
|
- Tagrisso - adjuvant NSCLC (EGFRm):
regulatory decision (US, CN)
- Imfinzi - new Q4W dosing: regulatory
decision (EU)
- Imfinzi - unresectable, Stage III NSCLC
(PACIFIC-2): data readout, regulatory submission
- Imfinzi - NSCLC (1st line) (PEARL):
data readout
- Imfinzi +/- treme15 - head & neck cancer (1st line):
data readout, regulatory submission
- Lynparza - pancreatic cancer (1st line,
BRCAm): regulatory decision (JP)
- Lynparza - prostate cancer (2nd line):
regulatory decision (JP)
- Lynparza - adjuvant breast cancer: data
readout
- Enhertu - gastric cancer (3rd line,
HER2+): regulatory decision (US)
- Calquence - CLL: regulatory decision
(JP)
- Calquence - CLL (2nd line) (ELEVATE
R/R): data readout, regulatory submission
- Koselugo - NF116 regulatory decision (EU)
- Forxiga - HF CVOT: regulatory decision
(CN)
- Brilique/Brilinta - CAD17/T2D CVOT: regulatory decision (EU, JP,
CN)
- Brilique - stroke (THALES): regulatory
decision (EU)
- Symbicort - mild asthma: regulatory
decision (EU)
- Fasenra - nasal polyps: regulatory
submission
- tezepelumab -
severe asthma: regulatory submission
- AZD7442 -
SARS-CoV-2: data readout, regulatory submission
|
H2 2021
|
- Imfinzi - ES-SCLC: regulatory decision
(CN)
- Imfinzi - NSCLC (1st line) (PEARL):
regulatory submission
- Imfinzi - adjuvant bladder cancer: data
readout
- Imfinzi - liver cancer (locoregional):
data readout, regulatory submission
- Imfinzi - biliary tract cancer: data
readout
- Imfinzi +/- treme - NSCLC (1st line)
(POSEIDON): data readout (OS18), regulatory submission
- Imfinzi +/- treme - liver cancer (1st
line): data readout, regulatory submission
- Lynparza - ovarian cancer (3rd line,
BRCAm): regulatory submission
- Lynparza - adjuvant breast cancer:
regulatory submission
- Lynparza - prostate cancer (1st line,
castration-resistant): data readout, regulatory
submission
- Enhertu - breast cancer (3rd line,
HER2+) (Phase III): data readout
- Enhertu - breast cancer (2nd line,
HER2+): data readout, regulatory submission
- Enhertu - breast cancer (HER2
low19): data readout
- Farxiga - HF (HFpEF20): data readout, regulatory
submission
- Brilinta - stroke (THALES): regulatory
decision (CN)
- PT027 - asthma:
data readout
- anifrolumab - lupus
(SLE): regulatory decision (US, EU)
|
|
YTD 2020
|
Q3 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Oncology
|
8,185
|
43
|
23
|
24
|
2,861
|
13
|
13
|
BioPharmaceuticals
|
7,291
|
38
|
3
|
5
|
2,350
|
(4)
|
(3)
|
- New CVRM
|
3,450
|
18
|
7
|
10
|
1,185
|
6
|
8
|
- Respiratory &
Immunology
|
3,841
|
20
|
(1)
|
1
|
1,165
|
(12)
|
(12)
|
Other
medicines
|
3,731
|
19
|
(6)
|
(4)
|
1,367
|
(5)
|
(3)
|
|
|
|
|
|
|
|
|
Total
|
19,207
|
100
|
8
|
10
|
6,578
|
3
|
3
|
Medicine
|
Therapy Area
|
YTD 2020
|
Q3 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
|||||
Tagrisso
|
Oncology
|
3,171
|
17
|
38
|
39
|
1,155
|
30
|
30
|
Symbicort
|
Respiratory & Immunology
|
2,042
|
11
|
15
|
16
|
599
|
(2)
|
(2)
|
Imfinzi
|
Oncology
|
1,487
|
8
|
42
|
43
|
533
|
29
|
29
|
Lynparza
|
Oncology
|
1,415
|
7
|
28
|
29
|
464
|
(12)
|
(12)
|
Farxiga
|
CVRM
|
1,377
|
7
|
22
|
26
|
527
|
32
|
35
|
Brilinta
|
CVRM
|
1,230
|
6
|
7
|
9
|
385
|
(7)
|
(7)
|
Nexium
|
Other medicines
|
1,140
|
6
|
(1)
|
1
|
409
|
7
|
8
|
Crestor
|
CVRM
|
884
|
5
|
(11)
|
(9)
|
301
|
(13)
|
(12)
|
Zoladex
|
Oncology
|
717
|
4
|
14
|
18
|
233
|
1
|
3
|
Fasenra
|
Respiratory & Immunology
|
666
|
3
|
34
|
34
|
240
|
19
|
18
|
|
|
|
|
|
|
|
|
|
Total
|
|
14,129
|
74
|
20
|
22
|
4,846
|
10
|
10
|
|
YTD 2020
|
Q3 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Lynparza: regulatory milestone
revenue
|
135
|
41
|
(48)
|
(48)
|
-
|
n/m
|
n/m
|
Enhertu: profit
share
|
63
|
19
|
n/m
|
n/m
|
27
|
n/m
|
n/m
|
Roxadustat: profit share
|
19
|
6
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
Other Collaboration Revenue
|
111
|
34
|
(23)
|
(23)
|
23
|
(69)
|
(69)
|
|
|
|
|
|
|
|
|
Total
|
328
|
100
|
(19)
|
(18)
|
58
|
(79)
|
(78)
|
Product Sales:
therapy area
|
Medicine
|
YTD 2020
|
|||
$m
|
% of total Product Sales
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
3,171
|
17
|
38
|
39
|
Imfinzi
|
1,487
|
8
|
42
|
43
|
|
Lynparza
|
1,280
|
7
|
51
|
53
|
|
Calquence
|
340
|
2
|
n/m
|
n/m
|
|
Koselugo
|
20
|
-
|
n/m
|
n/m
|
|
Zoladex
23
|
672
|
4
|
9
|
13
|
|
Faslodex\23
|
450
|
2
|
(38)
|
(37)
|
|
Iressa23
|
201
|
1
|
(41)
|
(40)
|
|
Arimidex23
|
149
|
1
|
(14)
|
(11)
|
|
Casodex23
|
133
|
1
|
(16)
|
(14)
|
|
Others
|
39
|
-
|
(44)
|
(43)
|
|
Total Oncology
|
7,942
|
42
|
24
|
26
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
1,373
|
7
|
22
|
26
|
Brilinta
|
1,230
|
7
|
7
|
9
|
|
Onglyza
|
365
|
2
|
(8)
|
(6)
|
|
Bydureon
|
326
|
2
|
(21)
|
(20)
|
|
Byetta
|
50
|
-
|
(40)
|
(38)
|
|
Other diabetes
|
35
|
-
|
(4)
|
(4)
|
|
Lokelma
|
48
|
-
|
n/m
|
n/m
|
|
Crestor23
|
882
|
5
|
(10)
|
(8)
|
|
Seloken/Toprol-XL23
|
620
|
3
|
9
|
14
|
|
Atacand23
|
180
|
1
|
11
|
18
|
|
Others
|
145
|
1
|
(27)
|
(26)
|
|
BioPharmaceuticals:
total CVRM
|
5,254
|
28
|
3
|
5
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
2,042
|
11
|
15
|
16
|
Fasenra
|
666
|
4
|
34
|
34
|
|
Pulmicort
|
628
|
3
|
(40)
|
(39)
|
|
Daliresp/Daxas
|
163
|
1
|
4
|
4
|
|
Bevespi
|
36
|
-
|
19
|
19
|
|
Breztri
|
21
|
-
|
n/m
|
n/m
|
|
Others
|
273
|
1
|
(17)
|
(16)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
3,829
|
20
|
(1)
|
1
|
|
Other medicines
|
Nexium23
|
1,115
|
6
|
(1)
|
1
|
Synagis23
|
294
|
2
|
-
|
-
|
|
Losec/Prilosec23
|
144
|
1
|
(34)
|
(32)
|
|
FluMist23
|
116
|
1
|
n/m
|
n/m
|
|
Seroquel XR/IR23
|
98
|
1
|
(35)
|
(34)
|
|
Others
|
87
|
-
|
(35)
|
(35)
|
|
Total other medicines
|
1,854
|
10
|
(5)
|
(4)
|
|
|
Total Product Sales
|
18,879
|
100
|
9
|
11
|
Total Collaboration Revenue
|
328
|
|
(19)
|
(18)
|
|
Total Revenue
|
19,207
|
|
8
|
10
|
Product Sales:
therapy area
|
Medicine
|
Q3 2020
|
|||
$m
|
% of total Product Sales
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
1,155
|
18
|
30
|
30
|
Imfinzi
|
533
|
8
|
29
|
29
|
|
Lynparza
|
464
|
7
|
42
|
42
|
|
Calquence
|
145
|
2
|
n/m
|
n/m
|
|
Koselugo
|
13
|
-
|
n/m
|
n/m
|
|
Zoladex
|
230
|
4
|
2
|
3
|
|
Faslodex
|
138
|
2
|
(33)
|
(32)
|
|
Iressa
|
54
|
1
|
(41)
|
(40)
|
|
Arimidex
|
42
|
1
|
(34)
|
(32)
|
|
Casodex
|
44
|
1
|
(16)
|
(16)
|
|
Others
|
13
|
-
|
(37)
|
(34)
|
|
Total Oncology
|
2,831
|
43
|
21
|
22
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
525
|
8
|
32
|
35
|
Brilinta
|
385
|
6
|
(7)
|
(7)
|
|
Onglyza
|
109
|
2
|
(14)
|
(13)
|
|
Bydureon
|
110
|
2
|
(14)
|
(14)
|
|
Byetta
|
15
|
-
|
(46)
|
(44)
|
|
Other diabetes
|
11
|
-
|
(19)
|
(20)
|
|
Lokelma
|
21
|
-
|
n/m
|
n/m
|
|
Crestor
|
300
|
5
|
(11)
|
(10)
|
|
Seloken/Toprol-XL
|
225
|
3
|
27
|
32
|
|
Atacand
|
54
|
1
|
(2)
|
4
|
|
Others
|
39
|
1
|
(41)
|
(41)
|
|
BioPharmaceuticals:
total CVRM
|
1,794
|
28
|
3
|
4
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
599
|
9
|
(2)
|
(2)
|
Fasenra
|
240
|
4
|
19
|
18
|
|
Pulmicort
|
151
|
2
|
(55)
|
(55)
|
|
Daliresp/Daxas
|
57
|
1
|
8
|
9
|
|
Bevespi
|
14
|
-
|
38
|
36
|
|
Breztri
|
10
|
-
|
n/m
|
n/m
|
|
Others
|
90
|
1
|
(12)
|
(13)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,161
|
18
|
(12)
|
(12)
|
|
Other medicines
|
Nexium
|
401
|
6
|
7
|
9
|
Synagis
|
118
|
2
|
(19)
|
(19)
|
|
Losec/Prilosec
|
45
|
1
|
(38)
|
(38)
|
|
FluMist
|
116
|
2
|
n/m
|
n/m
|
|
Seroquel XR/IR
|
35
|
1
|
(57)
|
(56)
|
|
Others
|
19
|
-
|
(56)
|
(57)
|
|
Total other medicines
|
734
|
11
|
1
|
1
|
|
|
Total Product Sales
|
6,520
|
100
|
6
|
7
|
|
Total Collaboration Revenue
|
58
|
|
(79)
|
(78)
|
|
Total Revenue
|
6,578
|
|
3
|
3
|
|
YTD 2020
|
Q3 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Emerging
Markets
|
6,466
|
34
|
6
|
11
|
2,137
|
-
|
4
|
- China
|
4,013
|
21
|
9
|
11
|
1,354
|
6
|
6
|
- Ex-China
|
2,453
|
13
|
3
|
10
|
783
|
(7)
|
2
|
|
|
|
|
|
|
|
|
US
|
6,445
|
34
|
12
|
12
|
2,268
|
11
|
11
|
|
|
|
|
|
|
|
|
Europe
|
3,709
|
19
|
6
|
7
|
1,262
|
(9)
|
(11)
|
|
|
|
|
|
|
|
|
Established
RoW
|
2,587
|
13
|
7
|
7
|
911
|
7
|
7
|
- Japan
|
1,902
|
10
|
2
|
1
|
670
|
1
|
1
|
- Canada
|
459
|
2
|
33
|
36
|
161
|
34
|
37
|
- Other Est. RoW
|
226
|
1
|
7
|
12
|
80
|
17
|
14
|
|
|
|
|
|
|
|
|
Total
|
19,207
|
100
|
8
|
10
|
6,578
|
3
|
3
|
|
YTD 2020
|
Q3 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Oncology
|
2,238
|
35
|
34
|
40
|
777
|
26
|
30
|
BioPharmaceuticals
|
2,125
|
33
|
(6)
|
(1)
|
646
|
(17)
|
(13)
|
- New CVRM
|
1,072
|
17
|
28
|
35
|
353
|
13
|
19
|
- Respiratory &
Immunology
|
1,053
|
16
|
(26)
|
(23)
|
293
|
(37)
|
(35)
|
Other medicines
|
2,103
|
33
|
(3)
|
1
|
714
|
(3)
|
1
|
|
|
|
|
|
|
|
|
Total
|
6,466
|
100
|
6
|
11
|
2,137
|
-
|
4
|
|
YTD 2020
|
Q3 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Tagrisso
|
950
|
15
|
72
|
78
|
355
|
59
|
61
|
Forxiga
|
488
|
8
|
44
|
54
|
181
|
37
|
47
|
Brilinta
|
392
|
6
|
13
|
18
|
102
|
(22)
|
(20)
|
Lynparza25
|
195
|
3
|
94
|
n/m
|
75
|
79
|
88
|
|
YTD 2020
|
Q3 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Ex-China Asia Pacific
|
896
|
5
|
7
|
299
|
4
|
7
|
Middle East and Africa
|
768
|
-
|
3
|
237
|
(15)
|
(12)
|
Ex-Brazil Latin America
|
317
|
-
|
16
|
110
|
2
|
20
|
Russia
|
237
|
34
|
45
|
62
|
(4)
|
8
|
Brazil
|
235
|
(14)
|
10
|
74
|
(27)
|
1
|
|
YTD 2020
|
YTD 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
19,207
|
17,720
|
8
|
10
|
- Product
Sales
|
18,879
|
17,315
|
9
|
11
|
- Collaboration
Revenue
|
328
|
405
|
(19)
|
(18)
|
|
|
|
|
|
Cost of Sales
|
(3,774)
|
(3,543)
|
7
|
9
|
|
|
|
|
|
Gross Profit
|
15,433
|
14,177
|
9
|
10
|
Gross Profit Margin
|
80.0%
|
79.5%
|
-
|
-
|
|
|
|
|
|
Distribution Expense
|
(290)
|
(247)
|
17
|
21
|
% Total Revenue
|
1.5%
|
1.4%
|
-
|
-
|
R&D Expense
|
(4,272)
|
(3,968)
|
8
|
8
|
% Total Revenue
|
22.2%
|
22.4%
|
-
|
-
|
SG&A Expense
|
(8,084)
|
(8,656)
|
(7)
|
(5)
|
% Total Revenue
|
42.1%
|
48.9%
|
+7
|
+7
|
|
|
|
|
|
Other Operating Income & Expense
|
888
|
1,041
|
(15)
|
(14)
|
% Total Revenue
|
4.6%
|
5.9%
|
-1
|
-1
|
|
|
|
|
|
Operating Profit
|
3,675
|
2,347
|
57
|
59
|
Operating Profit Margin
|
19.1%
|
13.2%
|
+6
|
+6
|
|
|
|
|
|
Net Finance Expense
|
(905)
|
(948)
|
(5)
|
(5)
|
Joint Ventures and Associates
|
(21)
|
(91)
|
(76)
|
(75)
|
|
|
|
|
|
Profit Before Tax
|
2,749
|
1,308
|
n/m
|
n/m
|
|
|
|
|
|
Taxation
|
(610)
|
(358)
|
70
|
71
|
Tax Rate
|
22%
|
27%
|
|
|
|
|
|
|
|
Profit After Tax
|
2,139
|
950
|
n/m
|
n/m
|
|
|
|
|
|
EPS
|
$1.66
|
$0.79
|
n/m
|
n/m
|
|
Q3 2020
|
Q3 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
6,578
|
6,406
|
3
|
3
|
- Product
Sales
|
6,520
|
6,132
|
6
|
7
|
- Collaboration
Revenue
|
58
|
274
|
(79)
|
(78)
|
|
|
|
|
|
Cost of Sales
|
(1,370)
|
(1,351)
|
1
|
-
|
|
|
|
|
|
Gross Profit
|
5,208
|
5,055
|
3
|
4
|
Gross Profit Margin
|
79.0%
|
78.0%
|
+1
|
+1
|
|
|
|
|
|
Distribution Expense
|
(99)
|
(88)
|
13
|
13
|
% Total Revenue
|
1.5%
|
1.4%
|
-
|
-
|
R&D Expense
|
(1,495)
|
(1,346)
|
11
|
11
|
% Total Revenue
|
22.7%
|
21.0%
|
-2
|
-2
|
SG&A Expense
|
(2,730)
|
(3,199)
|
(15)
|
(15)
|
% Total Revenue
|
41.5%
|
49.9%
|
+8
|
+9
|
|
|
|
|
|
Other Operating Income & Expense
|
287
|
335
|
(14)
|
(15)
|
% Total Revenue
|
4.4%
|
5.2%
|
-1
|
-1
|
|
|
|
|
|
Operating Profit
|
1,171
|
757
|
55
|
61
|
Operating Profit Margin
|
17.8%
|
11.8%
|
+6
|
+7
|
|
|
|
|
|
Net Finance Expense
|
(317)
|
(316)
|
1
|
(2)
|
Joint Ventures and Associates
|
(1)
|
(32)
|
(96)
|
(96)
|
|
|
|
|
|
Profit Before Tax
|
853
|
409
|
n/m
|
n/m
|
|
|
|
|
|
Taxation
|
(202)
|
(129)
|
57
|
63
|
Tax Rate
|
24%
|
32%
|
|
|
|
|
|
|
|
Profit After Tax
|
651
|
280
|
n/m
|
n/m
|
|
|
|
|
|
EPS
|
$0.49
|
$0.23
|
n/m
|
n/m
|
|
YTD 2020
|
YTD 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit Before Tax
|
2,749
|
1,308
|
n/m
|
n/m
|
Net Finance Expense
|
905
|
948
|
(5)
|
(5)
|
Joint Ventures and Associates
|
21
|
91
|
(76)
|
(75)
|
Depreciation, Amortisation and Impairment
|
2,352
|
2,119
|
11
|
12
|
|
|
|
|
|
EBITDA
|
6,027
|
4,466
|
35
|
37
|
|
Q3 2020
|
Q3 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit Before Tax
|
853
|
409
|
n/m
|
n/m
|
Net Finance Expense
|
317
|
316
|
1
|
(2)
|
Joint Ventures and Associates
|
1
|
32
|
(96)
|
(96)
|
Depreciation, Amortisation and Impairment
|
801
|
716
|
12
|
11
|
|
|
|
|
|
EBITDA
|
1,972
|
1,473
|
34
|
37
|
YTD 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core27
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
15,433
|
44
|
50
|
-
|
4
|
15,531
|
8
|
10
|
Gross Profit Margin
|
80.0%
|
|
|
|
|
80.5%
|
-
|
-
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(290)
|
-
|
-
|
-
|
-
|
(290)
|
17
|
21
|
R&D Expense
|
(4,272)
|
30
|
77
|
-
|
-
|
(4,165)
|
9
|
9
|
SG&A Expense
|
(8,084)
|
67
|
1,228
|
246
|
19
|
(6,524)
|
1
|
3
|
Total Operating Expense
|
(12,646)
|
97
|
1,305
|
246
|
19
|
(10,979)
|
4
|
5
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
888
|
(1)
|
2
|
-
|
-
|
889
|
(16)
|
(15)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
3,675
|
140
|
1,357
|
246
|
23
|
5,441
|
11
|
13
|
Operating Profit Margin
|
19.1%
|
|
|
|
|
28.3%
|
+1
|
+1
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(905)
|
-
|
-
|
174
|
154
|
(577)
|
-
|
(2)
|
Taxation
|
(610)
|
(28)
|
(284)
|
(92)
|
(1)
|
(1,015)
|
11
|
13
|
|
|
|
|
|
|
|
|
|
EPS
|
$1.66
|
$0.09
|
$0.82
|
$0.25
|
$0.13
|
$2.95
|
13
|
16
|
Q3 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core37
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
5,208
|
9
|
17
|
-
|
(1)
|
5,233
|
2
|
3
|
Gross Profit Margin
|
79.0%
|
|
|
|
|
79.4%
|
-
|
-
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(99)
|
-
|
-
|
-
|
-
|
(99)
|
13
|
13
|
R&D Expense
|
(1,495)
|
14
|
28
|
-
|
-
|
(1,453)
|
10
|
10
|
SG&A Expense
|
(2,730)
|
22
|
419
|
94
|
24
|
(2,171)
|
(1)
|
(1)
|
Total Operating Expense
|
(4,324)
|
36
|
447
|
94
|
24
|
(3,723)
|
3
|
3
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
287
|
(3)
|
1
|
-
|
-
|
285
|
(19)
|
(20)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
1,171
|
42
|
465
|
94
|
23
|
1,795
|
(4)
|
(1)
|
Operating Profit Margin
|
17.8%
|
|
|
|
|
27.3%
|
-2
|
-1
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(317)
|
-
|
-
|
59
|
50
|
(208)
|
10
|
8
|
Taxation
|
(202)
|
(8)
|
(101)
|
(32)
|
|
(343)
|
(10)
|
(7)
|
|
|
|
|
|
|
|
|
|
EPS
|
$0.49
|
$0.03
|
$0.28
|
$0.09
|
$0.05
|
$0.94
|
(4)
|
-
|
|
YTD 2020
|
YTD 2019
|
Change
|
$m
|
$m
|
$m
|
|
Reported Operating Profit
|
3,675
|
2,347
|
1,328
|
Depreciation, Amortisation and Impairment
|
2,352
|
2,119
|
233
|
|
|
|
|
Increase in Working Capital and Short-Term Provisions
|
(255)
|
(812)
|
557
|
Gains on Disposal of Intangible Assets
|
(535)
|
(833)
|
298
|
Non-Cash and Other Movements
|
(498)
|
313
|
(811)
|
Interest Paid
|
(517)
|
(575)
|
58
|
Taxation Paid
|
(1,221)
|
(965)
|
(256)
|
|
|
|
|
Net Cash Inflow from Operating Activities
|
3,001
|
1,594
|
1,407
|
|
|
|
|
Net Cash Inflow before Financing Activities
|
2,578
|
879
|
1,699
|
|
|
|
|
Net Cash Inflow/(Outflow) from Financing Activities
|
7
|
(1,771)
|
1,778
|
|
At 30 Sep 2020
|
At 31 Dec 2019
|
At 30 Sep 2019
|
$m
|
$m
|
$m
|
|
Cash
and cash equivalents
|
8,072
|
5,369
|
3,967
|
Other
investments
|
374
|
911
|
909
|
|
|
|
|
Cash and investments
|
8,446
|
6,280
|
4,876
|
|
|
|
|
Overdrafts
and short-term borrowings
|
(1,216)
|
(225)
|
(228)
|
Lease
liabilities
|
(666)
|
(675)
|
(712)
|
Current
instalments of loans
|
(2,186)
|
(1,597)
|
-
|
Non-current
instalments of loans
|
(18,271)
|
(15,730)
|
(17,218)
|
|
|
|
|
Interest-bearing loans and borrowings
(Gross Debt)
|
(22,339)
|
(18,227)
|
(18,158)
|
|
|
|
|
Net
derivatives
|
131
|
43
|
(16)
|
Net Debt
|
(13,762)
|
(11,904)
|
(13,298)
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5% Strengthening in Exchange Rate versus USD
($m)29
|
|||
Currency
|
Primary Relevance
|
FY 201930
|
YTD 202031
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product
Sales
|
6.92
|
7.00
|
(1)
|
288
|
190
|
EUR
|
Product
Sales
|
0.89
|
0.89
|
-
|
171
|
68
|
JPY
|
Product
Sales
|
108.98
|
107.51
|
1
|
139
|
98
|
Other32
|
|
|
|
|
231
|
123
|
|
|
|
|
|
|
|
GBP
|
Operating
Expense
|
0.78
|
0.79
|
-
|
27
|
(93)
|
SEK
|
Operating
Expense
|
9.46
|
9.40
|
1
|
5
|
(51)
|
New
molecular entities and major lifecycle events for medicines in
Phase III trials or under regulatory review
|
20
|
Oncology
- Tagrisso - NSCLC
- Imfinzi - multiple cancers
- Lynparza - multiple
cancers
- Enhertu - multiple cancers
- capivasertib -
breast, prostate cancer
- Calquence - blood cancers
- tremelimumab -
multiple cancers
- savolitinib -
NSCLC35
- monalizumab - head
& neck cancer
CVRM
- Farxiga - multiple
indications
- roxadustat -
anaemia in CKD
Respiratory & Immunology
- Fasenra - multiple
indications
- Breztri/Trixeo - COPD
- PT027 -
asthma
- tezepelumab -
severe asthma
- nirsevimab -
respiratory syncytial virus
- anifrolumab - lupus
(SLE)
- brazikumab -
inflammatory bowel disease
COVID-19
- AZD1222 -
SARS-CoV-2
- AZD7424 -
SARS-CoV-2
|
Total
projects
in
clinical development
|
148
|
|
Total
projects
in
total pipeline
|
172
|
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
NeoADAURA
|
Neo-adjuvant
EGFRm
NSCLC
|
Placebo
or Tagrisso
|
FPCD36
Q2
2020
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
ADAURA
|
Adjuvant
EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2015
LPCD37
Q1
2019
|
Trial
unblinded early due to overwhelming efficacy
|
Phase
III
LAURA
|
Locally
advanced, unresectable EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
FLAURA2
|
1st-line
EGFRm NSCLC
|
Tagrisso or Tagrisso
+ platinum-based chemotherapy doublet
|
FPCD
Q4
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
AEGEAN
|
Neo-adjuvant
(before surgery) NSCLC
|
SoC
chemotherapy +/- Imfinzi,
followed
by
surgery,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
ADJUVANT
BR.3138
|
Stage
Ib-IIIa resected NSCLC
|
Placebo or
Imfinzi
|
FPCD
Q1
2015
LPCD
Q1
2020
First
data anticipated
2021+
|
Recruitment
completed
|
Phase
III
MERMAID-1
|
Stage
II-III
resected
NSCLC
|
SoC
chemotherapy +/- Imfinzi
|
FPCDQ3
2020
First
data anticipated
2021+
|
Recruitmentongoing
|
Phase
III
PACIFIC-2
|
Stage
III unresectable locally advanced NSCLC
(concurrent
CRT)
|
Placebo or
Imfinzi
|
FPCD
Q2
2018
LPCD
Q3
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
Phase
III
ADRIATIC
|
Limited-
stage
SCLC
|
Concurrent
CRT,
followed
by
placebo
or
Imfinzi or Imfinzi +
treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
PEARL
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or Imfinzi
|
FPCD
Q1
2017
LPCD
Q1
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
Phase
III
POSEIDON
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC +
Imfinzi or SoC +
Imfinzi +
treme
|
FPCD
Q2
2017
LPCD
Q4
2018
OS data
anticipated
H2
2021
|
PFS
primary endpoint met
|
Phase
III
CASPIAN
|
ES-SCLC
|
SoC
chemotherapy or SoC +
Imfinzi or SoC +
Imfinzi +
treme
|
FPCD
Q1
2017
LPCD
Q2
2018
|
OS
primary endpoint met for Imfinzi
OS
primary endpoint not met for Imfinzi + treme
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
POTOMAC
|
Non-muscle
invasive bladder cancer
|
SoC
BCG39 or SoC BCG + Imfinzi
|
FPCD
Q4
2018LPCDQ3 2020
First
data
anticipated
2021+
|
Recruitmentcompleted
|
Phase
III
NIAGARA
|
Muscle-invasive
bladder cancer
|
Neo-adjuvant
cisplatin and gemcitabine SoC chemotherapy or SoC + Imfinzi, followed by adjuvant placebo
or Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
Phase
III
EMERALD-1
|
Locoregional
HCC40
|
TACE41
followed by placebo or TACE + Imfinzi, followed by Imfinzi +
bevacizumab
or
TACE +
Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
Phase
III
EMERALD-2
|
Locoregional
HCC at high risk of recurrence after surgery or radiofrequency
ablation
|
Adjuvant
Imfinzi or Imfinzi + bevacizumab
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
CALLA
|
Locally
advanced cervical cancer
|
CRT or
CRT + Imfinzi, followed by
placebo or Imfinzi
|
FPCD
Q1
2019
LPCDQ4
2020
First
data anticipated
2021+
|
Recruitment
completed
|
Phase
III
|
Resectable
gastric
and gastroesophageal cancer
|
Chemotherapy
or chemotherapy +
Imfinzi
|
Initiating
|
Initiating
|
Phase
IIIKUNLUN
|
Locally
advanced, unresectable oesophageal squamous cell
carcinoma
|
Definitive
CRT or CRT + Imfinzi
|
FPCDQ4
2020First data anticipated2021+
|
Recruitmentongoing
|
Phase
III
NILE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
KESTREL
|
Stage
IV, 1st-line HNSCC42
|
SoC or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1
2021
|
Recruitment
completed
|
Phase
III
HIMALAYA
|
Stage
IV, 1st-line unresectable HCC
|
Sorafenib or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2017
LPCD
Q4
2019
First
data
anticipated
H2
2021
|
Recruitment
completed
Orphan
Drug Designation (ODD)43 (US)
|
Phase
III
TOPAZ-1
|
Stage
IV, 1st-line biliary-tract cancer
|
Gemcitabine
and cisplatin SoC chemotherapy or SoC + Imfinzi
|
FPCD
Q2
2019
First
data anticipated
H2
2021
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
OlympiA
|
Adjuvant
BRCAm breast cancer
|
SoC
placebo or Lynparza
|
FPCD
Q2
2014
LPCD
Q2
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
Phase
III
PROfound
|
Metastatic
castration-resistant 2nd-line+ HRRm
prostate
cancer
|
SoC
(abiraterone or enzalutamide) or Lynparza
|
FPCD
Q2
2017
LPCD
Q4
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
III
PAOLA-144
|
Advanced
1st-line
ovarian
cancer
|
Bevacizumab
maintenance or
bevacizumab
+
Lynparza maintenance
|
FPCD
Q2
2015
LPCD
Q2
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
II/III
GY005
|
Recurrent
platinum-resistant/refractory ovarian cancer
|
SoC
chemotherapy or cediranib or cediranib + Lynparza
|
FPCD
Q2
2016
(Phase
II)
FPCD
Q1
2019
(Phase
III)
First
data
anticipated
2021+
|
Recruitment
ongoing
(Phase
III component)
|
Phase
III
DuO-O
|
Advanced
1st-line
ovarian
cancer
|
Chemotherapy
+
bevacizumab
or
chemotherapy
+
bevacizumab
+
Imfinzi +/-
Lynparza maintenance
|
FPCD
Q1 2019
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
DuO-E
|
Advanced
1st-line
endometrial
cancer
|
Chemotherapy
or
chemotherapy
+
Imfinzi + Imfinzi
maintenance or
chemotherapy
+
Imfinzi followed by Imfinzi + Lynparza maintenance
|
FPCD
Q2 2020
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
PROpel
|
Stage
IV, advanced, castration-resistant prostate cancer
|
Abiraterone
or
abiraterone
+
Lynparza
|
FPCD
Q4
2018
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
Phase
III
LYNK-003
|
Stage
IV, 1st-line colorectal cancer
|
Bevacizumab
+ 5-FU45 maintenance or bevacizumab +
Lynparza maintenance or
Lynparza
maintenance
|
First
data
anticipated
2021+
|
Initiating
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
II
DESTINY-Breast01-U201
|
Stage
IV, HER2+47 breast cancer post trastuzumab
emtansine
|
Enhertu
|
FPCD
Q4
2017
LPCD
Q4
2018
|
Primary
objective met
Breakthrough
Therapy Designation (US)
|
Phase
III
DESTINY-Breast02-U301
|
Stage
IV, HER2+ breast cancer post trastuzumab emtansine
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast03-U302
|
Stage
IV, HER2+ breast cancer
|
Trastuzumab
emtansine or Enhertu
|
FPCD
Q4
2018LPCDQ2 2020
First
data anticipated
H2
2021
|
Recruitment completed
|
Phase
III
DESTINY-Breast04
|
Stage
IV, HER2-low breast cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast06
|
Stage
IV, HER2-low breast cancer post endocrine therapy
|
SoC
chemotherapy or Enhertu
|
FPCDQ3
2020
|
Recruitment
ongoing
|
Phase
II
DESTINY-Gastric01
|
Stage
IV, HER2+ gastric cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2017
LPCD
Q2
2019
|
Primary
endpoint met
Breakthrough
Therapy Designation
(US)
|
Phase
IIDESTINY-Gastric03
|
Stage
IV, HER2+ gastric cancer
|
SoC
chemotherapy or SoC + Enhertu
|
FPCDQ2
2020
|
Recruitmentongoing
|
Phase
II
DESTINY-PanTumour02
|
HER2
expressing tumours
|
Enhertu
|
FPCD
Q3
2020
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Farxiga
|
|
||||
Phase
III
DAPA-HF
|
c.4,500
patients with HF with reduced ejection fraction, with and without
T2D
|
Arm 1:
Farxiga 10mg or 5mg
QD48 + SoC
Arm 2:
placebo + SoC
|
Time to
first occurrence of CV death or hospitalisation due to HF or an
urgent HF visit
|
FPCD
Q1
2017
LPCD
Q4
2018
|
Primary
endpoint met
|
Phase
III
DELIVER
|
c.4,700
patients with HF (HFpEF) with and without T2D
|
Arm 1:
Farxiga 10mg
QD
Arm 2:
placebo
|
Time to
first occurrence of CV death or worsening HF
|
FPCD
Q4
2018
First
data anticipatedH2 2021
|
Recruitment
ongoing
Fast
Track designation (US)
|
Phase
III
DAPA-CKD
|
c.4,000
patients with CKD, with and without T2D
|
Arm 1:
Farxiga 10mg or 5mg
QD
Arm 2:
placebo
|
Time to
first occurrence of ≥ 50% sustained decline in eGFR or
reaching ESRD or CV death or renal death
|
FPCD
Q1
2017
LPCD
Q1
2020
|
Trial
stopped early based on recommendation from an IDMC49
Primary
endpoint and secondary endpoints met
Fast
Track designation (US)
|
Brilinta
|
|
||||
Phase
III THEMIS
|
c.19,000
patients with T2D and CAD without a history of MI or
stroke
|
Arm 1:
Brilinta 60mg
BID50
Arm 2:
placebo BID on a background of aspirin if not
contra-indicated51 or not tolerated
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD
Q1
2014
LPCD
Q2
2016
|
Primary
endpoint met
|
Phase
III
THALES
|
c.11,000
patients with acute ischaemic stroke52 or transient ischaemic
attack
|
Arm 1:
Brilinta 90mg
BID
Arm 2:
placebo BID on a background of aspirin if not contra-indicated or
not tolerated
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD
Q1
2018
LPCD
Q4
2019
|
Primary
endpoint met
Fast
Track
designation
(US)
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Phase
III OSTRO
|
Patients
aged 18-75 years with severe bilateral nasal polyps; symptomatic,
despite SoC
|
Nasal-polyps
burden and reported nasal blockage
|
FPCD
Q1
2018
LPCD
Q2
2019
|
Co-primary
endpoints met
|
|
Phase
III RESOLUTE
|
Patients
with moderate to very severe COPD with a history of frequent COPD
exacerbations and elevated peripheral blood
eosinophils
|
Placebo
or Fasenra 100mg Q8W
SC
|
Annualised
rate of moderate or severe COPD exacerbations
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
|
Phase
III
MANDARA
|
Eosinophilic
granulomatosis with polyangiitis59
|
Fasenra 30mg or
mepolizumab
3x100mg Q4W
|
Proportion
of patients who achieve remission, defined as a score60 =0 and an OCS dose ≤4 mg/day at
weeks 36 and 48
|
FPCD
Q4
2019
Data
anticipated
2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
NATRON
|
HES61
|
Placebo
or Fasenra 30mg Q4W
SC
|
Time to
HES worsening flare or any cytotoxic and/or immuno-suppressive
therapy increase or hospitalisation
|
FPCD
Q3
2020
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
MESSINA
|
Eosinophilic
oesophagitis62
|
Placebo
or Fasenra 30mg Q4W
SC
|
Proportion
of patients with a histologic response63
|
FPCD
Q4
2020
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
FJORD
|
BP66
|
Placebo
or Fasenra 30mg Q4W
SC
|
Proportion
of patients with partial or
complete
remission of BP whilst off OCS for ≥2 months
at Week
36
|
Data
anticipated 2021+
|
Initiating
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
AZD1222
|
||||
Phase
I/II
COV00169
(UK)
|
Protection
against COVID-19 in participants aged 18-55
|
MenACWY
or
AZD1222
n=1,077
|
FPCD
Q2
2020
LPCD
Q2
2020
|
Initial
data readout
|
Phase
II/III
COV00279
(UK)
|
Protection
against COVID-19 in participants aged 18-55, 55+ and
paediatric
|
MenACWY
or
AZD1222
n=12,390
|
FPCD
Q2
2020
First
data anticipated
Q4
2020
|
Recruitment
ongoing
|
Phase
III
D8110C00001
(US,
global)
|
Protection
against COVID-19 in participants aged 18+
|
Placebo
or AZD1222
n=40,000
|
FPCD
Q3
2020
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
Phase
I/II
COV005ChAdOx1
nCoV-19 ZA70
(South
Africa)
|
Protection
against COVID-19 in participants aged 18-65
HIV+71
subgroup
|
Placebo
or AZD1222
n=2,020
|
FPCD
Q2
2020
First
data anticipated
Q4
2020
|
Recruitment
ongoing
|
Phase
II/III
COV00372
(Brazil)
|
Protection
against COVID-19 in participants aged 18-55
|
MenACWY
or
AZD1222
n=10,000
|
FPCD
Q2
2020
First
data anticipated
Q4
2020
|
Recruitment
ongoing
|
AZD7442
|
||||
Phase
I
|
COVID-19
|
Placebo
or AZD7442
|
-
|
Recruitment
completed
|
Phase
III
PROVENT
|
Protection
against COVID-19
(prophylaxis)
|
Placebo
or AZD7442
n=5,000
|
First
data anticipated
H1
2021
|
Initiating
|
Phase
III
STORMCHASER
|
Protection
against COVID-19
(post-exposure
prophylaxis)
|
Placebo
or AZD7442
n=1,125
|
First
data anticipated
H1
2021
|
Initiating
|
Phase
III
|
COVID-19
(treatment)
|
Current
SoC or AZD7442
n=c.4,000
|
First
data anticipated
H1
2021
|
Initiating
|
Acalabrutinib
|
||||
Phase
II
CALAVI
(US and
ex-US)
|
COVID-19
|
Current
SoC or SoC+ acalabrutinib
|
First
data anticipated
Q4
2020
|
Recruitment
completed
|
Farxiga
|
||||
Phase
III
DARE-19
|
COVID-19
|
Current
SoC or current SoC +
Farxiga
|
First
data anticipated
Q4
2020
|
Recruitment
ongoing
|
Phase
II
TACTIC-E73
|
COVID-19
|
Current
SoC or current SoC + Farxiga + ambrisentan
|
First
data anticipated
Q4
2020
|
Recruitment
ongoing
|
Symbicort
|
||||
Phase
IIIa
INHASCO74
|
COVID-19
|
Current
SoC or SoC + Symbicort
|
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
Pulmicort
|
||||
Phase
IIIa
TACTIC-COVID75
|
COVID-19
|
Current
SoC or SoC + Pulmicort
|
First
data anticipated
Q4
2020
|
Recruitment
ongoing
|
Phase
IIIa
STOIC76
|
COVID-19
|
Current
SoC or SoC + Pulmicort
|
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
MEDI3506
|
||||
Phase
II
ACCORD77
|
COVID-19
|
Current
SoC or current SoC + MEDI3506
|
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
For the nine
months ended 30
September
|
2020
|
2019
|
$m
|
$m
|
|
Total Revenue
|
19,207
|
17,720
|
Product Sales
|
18,879
|
17,315
|
Collaboration Revenue
|
328
|
405
|
|
|
|
Cost of Sales
|
(3,774)
|
(3,543)
|
|
|
|
Gross Profit
|
15,433
|
14,177
|
|
|
|
Distribution costs
|
(290)
|
(247)
|
Research and development expense
|
(4,272)
|
(3,968)
|
Selling, general and administrative costs
|
(8,084)
|
(8,656)
|
Other operating income and expense
|
888
|
1,041
|
|
|
|
Operating Profit
|
3,675
|
2,347
|
Finance income
|
80
|
133
|
Finance expense
|
(985)
|
(1,081)
|
Share of after-tax losses in associates and joint
ventures
|
(21)
|
(91)
|
|
|
|
Profit Before Tax
|
2,749
|
1,308
|
Taxation
|
(610)
|
(358)
|
Profit for the period
|
2,139
|
950
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(191)
|
(151)
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
974
|
(136)
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
(1)
|
(1)
|
Tax on items that will not be reclassified to profit or
loss
|
(70)
|
21
|
|
712
|
(267)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(121)
|
(385)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
145
|
(491)
|
Fair value movements on cash flow hedges
|
2
|
(156)
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(115)
|
109
|
Fair value movements on derivatives designated in net investment
hedges
|
39
|
35
|
Costs of hedging
|
10
|
(35)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
7
|
62
|
|
(33)
|
(861)
|
Other comprehensive income/(loss) for the period, net of
tax
|
679
|
(1,128)
|
Total comprehensive income/(loss) for the period
|
2,818
|
(178)
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
2,184
|
1,022
|
Non-controlling interests
|
(45)
|
(72)
|
|
2,139
|
950
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
2,864
|
(107)
|
Non-controlling interests
|
(46)
|
(71)
|
|
2,818
|
(178)
|
Basic earnings per $0.25 Ordinary Share
|
$1.66
|
$0.79
|
Diluted earnings per $0.25 Ordinary Share
|
$1.66
|
$0.79
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,297
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,297
|
For the quarter ended 30 September
|
2020
|
2019
|
$m
|
$m
|
|
Total Revenue
|
6,578
|
6,406
|
Product Sales
|
6,520
|
6,132
|
Collaboration Revenue
|
58
|
274
|
Cost of Sales
|
(1,370)
|
(1,351)
|
Gross Profit
|
5,208
|
5,055
|
|
|
|
Distribution costs
|
(99)
|
(88)
|
Research and development expense
|
(1,495)
|
(1,346)
|
Selling, general and administrative costs
|
(2,730)
|
(3,199)
|
Other operating income and expense
|
287
|
335
|
|
|
|
Operating Profit
|
1,171
|
757
|
Finance income
|
7
|
37
|
Finance expense
|
(324)
|
(353)
|
Share of after-tax losses in associates and joint
ventures
|
(1)
|
(32)
|
|
|
|
Profit Before Tax
|
853
|
409
|
Taxation
|
(202)
|
(129)
|
Profit for the period
|
651
|
280
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
14
|
96
|
Net losses on equity investments measured at fair value through
other comprehensive income
|
(95)
|
(82)
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
(7)
|
1
|
Tax on items that will not be reclassified to profit or
loss
|
9
|
4
|
|
(79)
|
19
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
373
|
(299)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
162
|
(305)
|
Fair value movements on cash flow hedges
|
133
|
(113)
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(114)
|
95
|
Fair value movements on derivatives designated in net investment
hedges
|
(21)
|
44
|
Costs of hedging
|
6
|
(38)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
(22)
|
42
|
|
517
|
(574)
|
Other comprehensive income/(loss) for the period, net of
tax
|
438
|
(555)
|
Total comprehensive income/(loss) for the period
|
1,089
|
(275)
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
648
|
299
|
Non-controlling interests
|
3
|
(19)
|
|
651
|
280
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
1,087
|
(257)
|
Non-controlling interests
|
2
|
(18)
|
|
1,089
|
(275)
|
Basic earnings per $0.25 Ordinary Share
|
$0.49
|
$0.23
|
Diluted earnings per $0.25 Ordinary Share
|
$0.49
|
$0.23
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,312
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,312
|
|
At 30 Sep 2020
|
At 31 Dec 2019
|
At 30 Sep 2019
|
$m
|
$m
|
$m
|
|
Assets
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and equipment
|
7,707
|
7,688
|
7,317
|
Right-of-use assets
|
653
|
647
|
690
|
Goodwill
|
11,711
|
11,668
|
11,595
|
Intangible assets
|
20,613
|
20,833
|
21,454
|
Investments in associates and joint ventures
|
42
|
58
|
43
|
Other investments
|
1,173
|
1,401
|
1,293
|
Derivative financial instruments
|
119
|
61
|
56
|
Other receivables
|
685
|
740
|
384
|
Deferred tax assets
|
3,243
|
2,718
|
2,554
|
|
45,946
|
45,814
|
45,386
|
Current assets
|
|
|
|
Inventories
|
3,683
|
3,193
|
3,129
|
Trade and other receivables
|
5,668
|
5,761
|
5,279
|
Other investments
|
374
|
849
|
813
|
Derivative financial instruments
|
37
|
36
|
9
|
Intangible assets
|
-
|
-
|
95
|
Income tax receivable
|
332
|
285
|
228
|
Cash and cash equivalents
|
8,072
|
5,369
|
3,967
|
Assets held for sale
|
-
|
70
|
-
|
|
18,166
|
15,563
|
13,520
|
Total assets
|
64,112
|
61,377
|
58,906
|
Liabilities
|
|
|
|
Current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(3,402)
|
(1,822)
|
(228)
|
Lease liabilities
|
(183)
|
(188)
|
(349)
|
Trade and other payables
|
(13,406)
|
(13,987)
|
(12,538)
|
Derivative financial instruments
|
(9)
|
(36)
|
(26)
|
Provisions
|
(621)
|
(723)
|
(401)
|
Income tax payable
|
(1,321)
|
(1,361)
|
(1,234)
|
|
(18,942)
|
(18,117)
|
(14,776)
|
Non-current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(18,271)
|
(15,730)
|
(17,218)
|
Lease liabilities
|
(483)
|
(487)
|
(363)
|
Derivative financial instruments
|
(16)
|
(18)
|
(55)
|
Deferred tax liabilities
|
(2,576)
|
(2,490)
|
(2,595)
|
Retirement benefit obligations
|
(2,895)
|
(2,807)
|
(2,392)
|
Provisions
|
(854)
|
(841)
|
(990)
|
Other payables
|
(6,457)
|
(6,291)
|
(6,848)
|
|
(31,552)
|
(28,664)
|
(30,461)
|
Total liabilities
|
(50,494)
|
(46,781)
|
(45,237)
|
Net assets
|
13,618
|
14,596
|
13,669
|
Equity
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
Share capital
|
328
|
328
|
328
|
Share premium account
|
7,952
|
7,941
|
7,919
|
Other reserves
|
2,039
|
2,046
|
2,052
|
Retained earnings
|
1,876
|
2,812
|
1,865
|
|
12,195
|
13,127
|
12,164
|
Non-controlling interests
|
1,423
|
1,469
|
1,505
|
Total equity
|
13,618
|
14,596
|
13,669
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2019
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards
|
-
|
-
|
-
|
54
|
54
|
-
|
54
|
Profit for the period
|
-
|
-
|
-
|
1,022
|
1,022
|
(72)
|
950
|
Other comprehensive loss
|
-
|
-
|
-
|
(1,129)
|
(1,129)
|
1
|
(1,128)
|
Transfer to other reserves
|
-
|
-
|
11
|
(11)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,583)
|
(3,583)
|
-
|
(3,583)
|
Issue of Ordinary Shares
|
11
|
3,492
|
-
|
-
|
3,503
|
-
|
3,503
|
Share-based payments charge for the period
|
-
|
-
|
-
|
154
|
154
|
-
|
154
|
Settlement of share plan awards
|
-
|
-
|
-
|
(325)
|
(325)
|
-
|
(325)
|
|
|
|
|
|
|
|
|
Net movement
|
11
|
3,492
|
11
|
(3,818)
|
(304)
|
(71)
|
(375)
|
|
|
|
|
|
|
|
|
At 30 Sep 2019
|
328
|
7,919
|
2,052
|
1,865
|
12,164
|
1,505
|
13,669
|
|
|
|
|
|
|
|
|
At 1 Jan 2020
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
2,184
|
2,184
|
(45)
|
2,139
|
Other comprehensive income
|
-
|
-
|
-
|
680
|
680
|
(1)
|
679
|
Transfer to other reserves
|
-
|
-
|
(7)
|
7
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,669)
|
(3,669)
|
-
|
(3,669)
|
Issue of Ordinary Shares
|
-
|
11
|
-
|
-
|
11
|
-
|
11
|
Share-based payments charge for the period
|
-
|
-
|
-
|
187
|
187
|
-
|
187
|
Settlement of share plan awards
|
-
|
-
|
-
|
(325)
|
(325)
|
-
|
(325)
|
|
|
|
|
|
|
|
|
Net movement
|
-
|
11
|
(7)
|
(936)
|
(932)
|
(46)
|
(978)
|
|
|
|
|
|
|
|
|
At 30 Sep 2020
|
328
|
7,952
|
2,039
|
1,876
|
12,195
|
1,423
|
13,618
|
For the nine
months ended 30
September
|
2020
|
2019
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
Profit Before Tax
|
2,749
|
1,308
|
Finance income and expense
|
905
|
948
|
Share of after-tax losses of associates and joint
ventures
|
21
|
91
|
Depreciation, amortisation and impairment
|
2,352
|
2,119
|
Increase in working capital and short-term provisions
|
(255)
|
(812)
|
Gains on disposal of intangible assets
|
(535)
|
(833)
|
Fair value movements on contingent consideration arising from
business combinations
|
(14)
|
(13)
|
Non-cash and other movements
|
(484)
|
326
|
|
|
|
Cash generated from operations
|
4,739
|
3,134
|
Interest paid
|
(517)
|
(575)
|
Tax paid
|
(1,221)
|
(965)
|
|
|
|
Net cash inflow from operating activities
|
3,001
|
1,594
|
|
|
|
Cash flows from investing activities
|
|
|
Payment of contingent consideration from business
combinations
|
(663)
|
(487)
|
Purchase of property, plant and equipment
|
(598)
|
(659)
|
Disposal of property, plant and equipment
|
67
|
31
|
Purchase of intangible assets
|
(1,460)
|
(1,416)
|
Disposal of intangible assets
|
664
|
1,400
|
Movement
in profit-participation liability
|
-
|
150
|
Purchase of non-current asset investments
|
(119)
|
(6)
|
Disposal of non-current asset investments
|
1,121
|
18
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
530
|
196
|
Payments to associates and joint ventures
|
(8)
|
(49)
|
Interest received
|
43
|
107
|
|
|
|
Net cash outflow from investing activities
|
(423)
|
(715)
|
|
|
|
Net cash inflow before financing activities
|
2,578
|
879
|
|
|
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
11
|
3,503
|
Issue of loans
|
2,968
|
500
|
Repayment of loans
|
-
|
(1,500)
|
Dividends paid
|
(3,572)
|
(3,592)
|
Hedge contracts relating to dividend payments
|
(101)
|
4
|
Repayment of obligations under leases
|
(157)
|
(131)
|
Movement in short-term borrowings
|
858
|
(555)
|
|
|
|
Net cash inflow/(outflow) from financing activities
|
7
|
(1,771)
|
|
|
|
Net increase/(decrease) in cash and cash equivalents in the
period
|
2,585
|
(892)
|
Cash and cash equivalents at the beginning of the
period
|
5,223
|
4,671
|
Exchange rate effects
|
(14)
|
-
|
|
|
|
Cash and cash equivalents at the end of the period
|
7,794
|
3,779
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
8,072
|
3,967
|
Overdrafts
|
(278)
|
(188)
|
|
|
|
|
7,794
|
3,779
|
|
At
1 Jan 2020
|
Cash flow
|
Non-cash & other
|
Exchange movements
|
At
30 Sep 2020
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
(15,730)
|
(2,968)
|
545
|
(118)
|
(18,271)
|
Non-current instalments of leases
|
(487)
|
-
|
2
|
2
|
(483)
|
|
|
|
|
|
|
Total long-term debt
|
(16,217)
|
(2,968)
|
547
|
(116)
|
(18,754)
|
|
|
|
|
|
|
Current instalments of loans
|
(1,597)
|
-
|
(557)
|
(32)
|
(2,186)
|
Current instalments of leases
|
(188)
|
172
|
(168)
|
1
|
(183)
|
Commercial paper
|
-
|
(793)
|
-
|
-
|
(793)
|
Bank collateral
|
(71)
|
(62)
|
-
|
-
|
(133)
|
Other short-term borrowings excluding overdrafts
|
(8)
|
(3)
|
-
|
(1)
|
(12)
|
Overdraft
|
(146)
|
(137)
|
-
|
5
|
(278)
|
|
|
|
|
|
|
Total current debt
|
(2,010)
|
(823)
|
(725)
|
(27)
|
(3,585)
|
|
|
|
|
|
|
Gross borrowings
|
(18,227)
|
(3,791)
|
(178)
|
(143)
|
(22,339)
|
|
|
|
|
|
|
Net derivative financial instruments
|
43
|
101
|
(13)
|
-
|
131
|
|
|
|
|
|
|
Net borrowings
|
(18,184)
|
(3,690)
|
(191)
|
(143)
|
(22,208)
|
|
|
|
|
|
|
Cash and cash equivalents
|
5,369
|
2,722
|
-
|
(19)
|
8,072
|
Other investments - current
|
849
|
(530)
|
61
|
(6)
|
374
|
Other investments - non-current
|
62
|
-
|
(62)
|
-
|
-
|
Cash and investments
|
6,280
|
2,192
|
(1)
|
(25)
|
8,446
|
|
|
|
|
|
|
Net Debt
|
(11,904)
|
(1,498)
|
(192)
|
(168)
|
(13,762)
|
|
2020
|
2019
|
||
Diabetes alliance
|
Other
|
Total
|
Total
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
3,300
|
839
|
4,139
|
5,106
|
Settlements
|
(394)
|
(269)
|
(663)
|
(487)
|
Revaluations
|
(22)
|
8
|
(14)
|
(13)
|
Discount unwind
|
174
|
38
|
212
|
269
|
|
|
|
|
|
At 30 September
|
3,058
|
616
|
3,674
|
4,875
|
7)
|
Table 41: Product Sales year-on-year analysis - YTD
202078
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
3,171
|
38
|
39
|
950
|
72
|
78
|
1,144
|
26
|
503
|
49
|
50
|
574
|
14
|
13
|
Imfinzi
|
1,487
|
42
|
43
|
113
|
n/m
|
n/m
|
885
|
17
|
254
|
n/m
|
n/m
|
235
|
53
|
53
|
Lynparza
|
1,280
|
51
|
53
|
195
|
94
|
n/m
|
631
|
46
|
311
|
50
|
51
|
143
|
34
|
34
|
Calquence
|
340
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
335
|
n/m
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
Koselugo
|
20
|
n/m
|
n/m
|
-
|
-
|
-
|
20
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex*
|
672
|
9
|
13
|
427
|
12
|
18
|
6
|
17
|
104
|
5
|
6
|
135
|
2
|
2
|
Faslodex*
|
450
|
(38)
|
(37)
|
142
|
(3)
|
3
|
45
|
(85)
|
171
|
2
|
3
|
92
|
(9)
|
(10)
|
Iressa*
|
201
|
(41)
|
(40)
|
163
|
(28)
|
(26)
|
10
|
(25)
|
11
|
(81)
|
(81)
|
17
|
(60)
|
(60)
|
Arimidex*
|
149
|
(14)
|
(11)
|
121
|
3
|
7
|
-
|
-
|
3
|
(88)
|
(88)
|
25
|
(27)
|
(27)
|
Casodex*
|
133
|
(16)
|
(14)
|
104
|
4
|
7
|
1
|
(93)
|
2
|
(84)
|
(84)
|
26
|
(42)
|
(41)
|
Others
|
39
|
(44)
|
(43)
|
20
|
(8)
|
(4)
|
1
|
n/m
|
4
|
(29)
|
(28)
|
14
|
(66)
|
(66)
|
Total Oncology
|
7,942
|
24
|
26
|
2,238
|
34
|
40
|
3,078
|
21
|
1,363
|
33
|
34
|
1,263
|
9
|
8
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
1,373
|
22
|
26
|
488
|
44
|
54
|
385
|
(3)
|
363
|
33
|
34
|
137
|
19
|
19
|
Brilinta
|
1,230
|
7
|
9
|
392
|
13
|
18
|
537
|
7
|
257
|
(2)
|
(1)
|
44
|
2
|
5
|
Onglyza
|
365
|
(8)
|
(6)
|
154
|
18
|
23
|
134
|
(23)
|
43
|
(19)
|
(19)
|
34
|
(10)
|
(9)
|
Bydureon
|
326
|
(21)
|
(20)
|
3
|
(70)
|
(68)
|
278
|
(18)
|
38
|
(24)
|
(23)
|
7
|
(30)
|
(26)
|
Byetta
|
50
|
(40)
|
(38)
|
8
|
1
|
7
|
24
|
(52)
|
11
|
(26)
|
(25)
|
7
|
(19)
|
(17)
|
Other diabetes
|
35
|
(4)
|
(4)
|
5
|
n/m
|
n/m
|
20
|
(30)
|
9
|
35
|
38
|
1
|
56
|
38
|
Lokelma
|
48
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
37
|
n/m
|
3
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
Crestor*
|
882
|
(10)
|
(8)
|
560
|
(10)
|
(7)
|
71
|
(19)
|
94
|
(16)
|
(15)
|
157
|
(3)
|
(3)
|
Seloken/Toprol-XL*
|
620
|
9
|
14
|
592
|
15
|
21
|
9
|
(69)
|
12
|
(37)
|
(37)
|
7
|
(12)
|
(7)
|
Atacand*
|
180
|
11
|
18
|
133
|
14
|
21
|
7
|
(11)
|
22
|
-
|
-
|
18
|
24
|
27
|
Others
|
145
|
(27)
|
(26)
|
93
|
(33)
|
(31)
|
-
|
-
|
45
|
(2)
|
(1)
|
7
|
(55)
|
(54)
|
BioPharmaceuticals: total CVRM
|
5,254
|
3
|
5
|
2,431
|
9
|
15
|
1,502
|
(7)
|
897
|
5
|
6
|
424
|
2
|
3
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
2,042
|
15
|
16
|
423
|
6
|
11
|
755
|
29
|
521
|
3
|
4
|
343
|
18
|
20
|
Fasenra
|
666
|
34
|
34
|
10
|
n/m
|
n/m
|
423
|
23
|
140
|
72
|
74
|
93
|
34
|
34
|
Pulmicort
|
628
|
(40)
|
(39)
|
479
|
(43)
|
(42)
|
53
|
(40)
|
55
|
(8)
|
(6)
|
41
|
(32)
|
(32)
|
Daliresp/Daxas
|
163
|
4
|
4
|
3
|
(12)
|
(9)
|
141
|
6
|
18
|
(7)
|
(6)
|
1
|
(8)
|
(6)
|
Bevespi
|
36
|
19
|
19
|
1
|
n/m
|
n/m
|
33
|
11
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
Breztri
|
21
|
n/m
|
n/m
|
14
|
n/m
|
n/m
|
3
|
n/m
|
-
|
-
|
-
|
4
|
n/m
|
n/m
|
Others
|
273
|
(17)
|
(16)
|
122
|
(27)
|
(25)
|
8
|
n/m
|
132
|
(12)
|
(11)
|
11
|
(5)
|
(2)
|
BioPharmaceuticals: total Respiratory & Immunology
|
3,829
|
(1)
|
1
|
1,052
|
(26)
|
(23)
|
1,416
|
20
|
868
|
6
|
7
|
493
|
14
|
15
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
1,115
|
(1)
|
1
|
563
|
(2)
|
2
|
127
|
(28)
|
59
|
21
|
21
|
366
|
10
|
10
|
Synagis*
|
294
|
-
|
-
|
-
|
-
|
-
|
47
|
29
|
247
|
(5)
|
(5)
|
-
|
-
|
-
|
Losec/Prilosec*
|
144
|
(34)
|
(32)
|
119
|
(18)
|
(16)
|
3
|
(50)
|
17
|
(63)
|
(63)
|
5
|
(74)
|
(75)
|
FluMist*
|
116
|
n/m
|
n/m
|
-
|
-
|
-
|
65
|
n/m
|
49
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
Seroquel XR/IR*
|
98
|
(35)
|
(34)
|
41
|
(2)
|
1
|
22
|
(19)
|
21
|
(68)
|
(68)
|
14
|
(7)
|
(8)
|
Others
|
87
|
(35)
|
(35)
|
6
|
45
|
42
|
38
|
(53)
|
38
|
(15)
|
(15)
|
5
|
3
|
3
|
Total other medicines
|
1,854
|
(5)
|
(4)
|
729
|
(5)
|
(1)
|
302
|
(13)
|
431
|
(7)
|
(8)
|
392
|
5
|
5
|
Total Product Sales
|
18,879
|
9
|
11
|
6,450
|
6
|
11
|
6,298
|
11
|
3,559
|
12
|
13
|
2,572
|
8
|
8
|
8)
|
Table
42: Product Sales year-on-year analysis - Q3 202079
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
1,155
|
30
|
30
|
355
|
59
|
61
|
419
|
20
|
178
|
42
|
37
|
203
|
6
|
5
|
Imfinzi
|
533
|
29
|
29
|
50
|
n/m
|
n/m
|
311
|
9
|
87
|
59
|
55
|
85
|
30
|
29
|
Lynparza
|
464
|
42
|
42
|
75
|
79
|
88
|
224
|
32
|
114
|
48
|
44
|
51
|
33
|
33
|
Calquence
|
145
|
n/m
|
n/m
|
2
|
91
|
115
|
142
|
n/m
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
Koselugo
|
13
|
n/m
|
n/m
|
-
|
-
|
-
|
13
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex*
|
230
|
2
|
3
|
139
|
(4)
|
(1)
|
1
|
(1)
|
36
|
4
|
3
|
54
|
18
|
17
|
Faslodex*
|
138
|
(33)
|
(32)
|
41
|
(16)
|
(11)
|
12
|
(81)
|
54
|
(6)
|
(8)
|
31
|
(19)
|
(19)
|
Iressa*
|
54
|
(41)
|
(40)
|
43
|
(31)
|
(30)
|
3
|
(50)
|
3
|
(83)
|
(83)
|
5
|
(30)
|
(33)
|
Arimidex*
|
42
|
(34)
|
(32)
|
32
|
(31)
|
(29)
|
-
|
-
|
1
|
(83)
|
(84)
|
9
|
(15)
|
(15)
|
Casodex*
|
44
|
(16)
|
(16)
|
34
|
-
|
2
|
1
|
n/m
|
1
|
(79)
|
(84)
|
8
|
(42)
|
(39)
|
Others
|
13
|
(39)
|
(36)
|
6
|
8
|
22
|
1
|
n/m
|
1
|
(45)
|
(47)
|
5
|
(60)
|
(61)
|
Total Oncology
|
2,831
|
21
|
22
|
777
|
26
|
30
|
1,127
|
23
|
475
|
26
|
23
|
452
|
7
|
6
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
525
|
32
|
35
|
181
|
37
|
47
|
148
|
18
|
141
|
48
|
44
|
55
|
27
|
26
|
Brilinta
|
385
|
(7)
|
(7)
|
102
|
(22)
|
(20)
|
185
|
3
|
84
|
(8)
|
(11)
|
14
|
(5)
|
(5)
|
Onglyza
|
109
|
(14)
|
(13)
|
55
|
24
|
27
|
29
|
(47)
|
14
|
(18)
|
(19)
|
11
|
(1)
|
1
|
Bydureon
|
110
|
(14)
|
(14)
|
1
|
(55)
|
(51)
|
93
|
(13)
|
14
|
(14)
|
(16)
|
2
|
(7)
|
(3)
|
Byetta
|
15
|
(46)
|
(44)
|
3
|
(12)
|
(8)
|
6
|
(66)
|
3
|
(28)
|
(22)
|
3
|
(3)
|
(12)
|
Other diabetes
|
11
|
(19)
|
(20)
|
1
|
n/m
|
n/m
|
6
|
(44)
|
3
|
23
|
21
|
1
|
n/m
|
n/m
|
Lokelma
|
21
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
16
|
n/m
|
1
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
Crestor*
|
300
|
(11)
|
(10)
|
191
|
(11)
|
(9)
|
26
|
(23)
|
30
|
(18)
|
(19)
|
53
|
1
|
-
|
Seloken/Toprol-XL*
|
225
|
27
|
32
|
216
|
31
|
36
|
3
|
(17)
|
4
|
(30)
|
(30)
|
2
|
(30)
|
(25)
|
Atacand*
|
54
|
(2)
|
4
|
39
|
(5)
|
4
|
2
|
13
|
7
|
6
|
6
|
6
|
3
|
1
|
Others
|
39
|
(41)
|
(41)
|
28
|
(36)
|
(38)
|
-
|
-
|
10
|
(37)
|
(36)
|
1
|
(91)
|
(79)
|
BioPharmaceuticals: total CVRM
|
1,794
|
3
|
4
|
819
|
5
|
10
|
514
|
(4)
|
311
|
6
|
4
|
150
|
5
|
5
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
599
|
(2)
|
(2)
|
132
|
(4)
|
1
|
197
|
(3)
|
165
|
7
|
4
|
105
|
(11)
|
(11)
|
Fasenra
|
240
|
19
|
18
|
3
|
12
|
26
|
151
|
11
|
52
|
43
|
39
|
34
|
24
|
23
|
Pulmicort
|
151
|
(55)
|
(55)
|
109
|
(60)
|
(59)
|
17
|
(49)
|
14
|
(8)
|
(12)
|
11
|
(44)
|
(45)
|
Daliresp/Daxas
|
57
|
8
|
9
|
1
|
(10)
|
(13)
|
51
|
15
|
5
|
(30)
|
(33)
|
-
|
-
|
-
|
Bevespi
|
14
|
38
|
36
|
1
|
-
|
-
|
12
|
23
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Breztri
|
10
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
3
|
n/m
|
-
|
-
|
-
|
2
|
31
|
37
|
Others
|
90
|
(12)
|
(13)
|
42
|
(20)
|
(20)
|
1
|
(52)
|
44
|
(3)
|
(5)
|
3
|
(16)
|
(15)
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,161
|
(12)
|
(12)
|
293
|
(37)
|
(35)
|
432
|
1
|
281
|
9
|
6
|
155
|
(9)
|
(9)
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
401
|
7
|
9
|
193
|
(6)
|
(2)
|
47
|
(17)
|
22
|
34
|
25
|
139
|
45
|
45
|
Synagis*
|
118
|
(19)
|
(19)
|
(5)
|
-
|
-
|
26
|
n/m
|
97
|
(33)
|
(33)
|
-
|
-
|
-
|
Losec/Prilosec*
|
45
|
(38)
|
(38)
|
38
|
(23)
|
(24)
|
-
|
(83)
|
7
|
(50)
|
(52)
|
-
|
(98)
|
(97)
|
FluMist*
|
116
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
65
|
n/m
|
49
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
Seroquel XR/IR*
|
35
|
(57)
|
(56)
|
13
|
(22)
|
(19)
|
8
|
(81)
|
7
|
(66)
|
(65)
|
7
|
70
|
69
|
Others
|
19
|
(56)
|
(57)
|
3
|
n/m
|
n/m
|
5
|
(85)
|
10
|
(41)
|
(46)
|
1
|
n/m
|
n/m
|
Total other medicines
|
734
|
1
|
1
|
242
|
(9)
|
(6)
|
151
|
5
|
192
|
(10)
|
(12)
|
149
|
38
|
38
|
Total Product Sales
|
6,520
|
6
|
7
|
2,131
|
-
|
4
|
2,224
|
10
|
1,259
|
10
|
8
|
906
|
7
|
7
|
9)
|
Table
43: Product Sales quarterly sequential analysis - 202080
|
|
Q1 2020
|
Q2 2020
|
Q3 2020
|
|
|||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
|
|||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
982
|
11
|
11
|
1,034
|
5
|
7
|
1,155
|
12
|
9
|
|
|
Imfinzi
|
462
|
9
|
9
|
492
|
6
|
8
|
533
|
8
|
6
|
|
|
Lynparza
|
397
|
13
|
13
|
419
|
5
|
7
|
464
|
11
|
8
|
|
|
Calquence
|
88
|
58
|
58
|
107
|
21
|
23
|
145
|
36
|
35
|
|
|
Koselugo
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
13
|
75
|
75
|
|
|
Zoladex*
|
225
|
15
|
15
|
217
|
(3)
|
-
|
230
|
6
|
3
|
|
|
Faslodex*
|
166
|
-
|
-
|
146
|
(12)
|
(9)
|
138
|
(5)
|
(8)
|
|
|
Iressa*
|
77
|
(3)
|
(4)
|
70
|
(9)
|
(7)
|
54
|
(23)
|
(24)
|
|
|
Arimidex*
|
50
|
(1)
|
(2)
|
58
|
17
|
16
|
42
|
(28)
|
(27)
|
|
|
Casodex*
|
42
|
(2)
|
(3)
|
47
|
14
|
12
|
44
|
(7)
|
(8)
|
|
|
Others
|
13
|
(52)
|
(52)
|
12
|
(11)
|
(1)
|
13
|
4
|
3
|
|
|
Total Oncology
|
2,502
|
10
|
10
|
2,609
|
4
|
6
|
2,831
|
8
|
6
|
|
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
405
|
(3)
|
(3)
|
443
|
9
|
13
|
525
|
19
|
16
|
|
|
Brilinta
|
408
|
(5)
|
(5)
|
437
|
7
|
9
|
385
|
(12)
|
(13)
|
|
|
Onglyza
|
141
|
8
|
8
|
115
|
(19)
|
(17)
|
110
|
(6)
|
(6)
|
|
|
Bydureon
|
100
|
(28)
|
(28)
|
116
|
16
|
17
|
109
|
(5)
|
(7)
|
|
|
Byetta
|
20
|
(24)
|
(24)
|
15
|
(28)
|
(28)
|
15
|
1
|
4
|
|
|
Other diabetes
|
13
|
(22)
|
(22)
|
10
|
(21)
|
(19)
|
11
|
9
|
6
|
|
|
Lokelma
|
11
|
42
|
42
|
17
|
56
|
58
|
21
|
22
|
26
|
|
|
Crestor*
|
301
|
2
|
1
|
281
|
(7)
|
(4)
|
300
|
7
|
5
|
|
|
Seloken/Toprol-XL*
|
177
|
(6)
|
(6)
|
218
|
23
|
27
|
225
|
4
|
3
|
|
|
Atacand*
|
66
|
11
|
12
|
59
|
(11)
|
(5)
|
54
|
(9)
|
(12)
|
|
|
Others
|
59
|
(21)
|
(22)
|
48
|
(18)
|
(16)
|
39
|
(19)
|
(22)
|
|
|
BioPharmaceuticals: total CVRM
|
1,701
|
(5)
|
(5)
|
1,759
|
3
|
6
|
1,794
|
2
|
-
|
|
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
790
|
11
|
11
|
653
|
(17)
|
(15)
|
599
|
(8)
|
(11)
|
|
|
Fasenra
|
199
|
(3)
|
(3)
|
227
|
14
|
15
|
240
|
5
|
4
|
|
|
Pulmicort
|
380
|
(8)
|
(9)
|
97
|
(74)
|
(73)
|
151
|
56
|
49
|
|
|
Daliresp/Daxas
|
53
|
(8)
|
(8)
|
53
|
(1)
|
(3)
|
57
|
8
|
11
|
|
|
Bevespi
|
12
|
9
|
9
|
10
|
(19)
|
(21)
|
14
|
47
|
46
|
|
|
Breztri
|
4
|
n/m
|
n/m
|
7
|
58
|
64
|
10
|
45
|
48
|
|
|
Others
|
113
|
(16)
|
(17)
|
70
|
(38)
|
(36)
|
90
|
27
|
22
|
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,551
|
1
|
1
|
1,117
|
(28)
|
(26)
|
1,161
|
4
|
1
|
|
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
338
|
(4)
|
(4)
|
377
|
12
|
14
|
401
|
6
|
4
|
|
|
Synagis*
|
85
|
35
|
35
|
90
|
6
|
7
|
118
|
31
|
29
|
|
|
Losec/Prilosec*
|
54
|
18
|
17
|
45
|
(15)
|
(15)
|
45
|
-
|
-
|
|
|
FluMist*
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
116
|
n/m
|
n/m
|
|
|
Seroquel XR/IR*
|
36
|
(12)
|
(12)
|
27
|
(26)
|
(23)
|
35
|
32
|
29
|
|
|
Others
|
44
|
(71)
|
(70)
|
24
|
(46)
|
(42)
|
19
|
(17)
|
(19)
|
|
|
Total other medicines
|
557
|
(15)
|
(15)
|
563
|
1
|
4
|
734
|
30
|
27
|
|
|
Total Product Sales
|
6,311
|
1
|
1
|
6,048
|
(4)
|
(2)
|
6,520
|
8
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10)
|
Table
44: Product Sales quarterly sequential analysis - 201981
|
|
Q1 2019
|
Q2 2019
|
Q3 2019
|
Q4 2019
|
||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
630
|
6
|
6
|
784
|
24
|
25
|
891
|
14
|
13
|
884
|
(1)
|
-
|
Imfinzi
|
295
|
13
|
13
|
338
|
15
|
15
|
412
|
22
|
22
|
424
|
3
|
4
|
Lynparza
|
237
|
13
|
13
|
283
|
19
|
20
|
327
|
16
|
15
|
351
|
7
|
8
|
Calquence
|
29
|
21
|
23
|
35
|
21
|
19
|
44
|
27
|
27
|
56
|
25
|
25
|
Faslodex*
|
254
|
(6)
|
(6)
|
267
|
5
|
6
|
205
|
(23)
|
(23)
|
166
|
(20)
|
(19)
|
Zoladex*
|
194
|
7
|
6
|
197
|
2
|
1
|
226
|
15
|
16
|
196
|
(14)
|
(12)
|
Iressa*
|
134
|
20
|
18
|
118
|
(12)
|
(11)
|
91
|
(23)
|
(22)
|
80
|
(13)
|
(12)
|
Arimidex*
|
51
|
11
|
10
|
60
|
18
|
17
|
63
|
5
|
5
|
51
|
(20)
|
(18)
|
Casodex*
|
48
|
4
|
3
|
57
|
19
|
18
|
52
|
(8)
|
(6)
|
43
|
(18)
|
(17)
|
Others
|
20
|
(13)
|
(14)
|
28
|
40
|
29
|
20
|
(27)
|
(22)
|
26
|
30
|
26
|
Total Oncology
|
1,892
|
7
|
6
|
2,167
|
15
|
15
|
2,334
|
8
|
8
|
2,274
|
(3)
|
(2)
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
349
|
(12)
|
(12)
|
377
|
8
|
9
|
398
|
5
|
5
|
419
|
5
|
6
|
Brilinta
|
348
|
(7)
|
(8)
|
389
|
12
|
12
|
416
|
7
|
8
|
428
|
3
|
3
|
Onglyza
|
153
|
3
|
3
|
116
|
(24)
|
(24)
|
127
|
9
|
11
|
131
|
3
|
4
|
Bydureon
|
142
|
3
|
3
|
141
|
(1)
|
-
|
127
|
(10)
|
(10)
|
139
|
9
|
10
|
Byetta
|
30
|
(6)
|
(5)
|
25
|
(17)
|
(16)
|
28
|
10
|
13
|
27
|
(2)
|
(4)
|
Other diabetes
|
11
|
(8)
|
(17)
|
11
|
-
|
8
|
14
|
26
|
22
|
16
|
17
|
17
|
Lokelma
|
-
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
8
|
87
|
74
|
Crestor*
|
335
|
(5)
|
(6)
|
310
|
(7)
|
(7)
|
337
|
9
|
9
|
296
|
(12)
|
(11)
|
Seloken/Toprol-XL*
|
225
|
41
|
38
|
168
|
(25)
|
(25)
|
177
|
6
|
8
|
190
|
7
|
8
|
Atacand*
|
50
|
(14)
|
(15)
|
56
|
12
|
14
|
55
|
(1)
|
(1)
|
60
|
8
|
9
|
Others
|
71
|
(3)
|
(5)
|
63
|
(11)
|
(8)
|
65
|
4
|
2
|
72
|
13
|
16
|
BioPharmaceuticals: total CVRM
|
1,714
|
(2)
|
(3)
|
1,658
|
(3)
|
(3)
|
1,749
|
5
|
6
|
1,785
|
2
|
3
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
585
|
(8)
|
(8)
|
585
|
-
|
1
|
613
|
5
|
4
|
712
|
16
|
17
|
Pulmicort
|
383
|
(2)
|
(2)
|
333
|
(13)
|
(13)
|
337
|
1
|
3
|
413
|
22
|
23
|
Fasenra
|
129
|
3
|
4
|
167
|
29
|
30
|
202
|
21
|
21
|
206
|
2
|
2
|
Daliresp/Daxas
|
48
|
(11)
|
(12)
|
56
|
17
|
18
|
53
|
(6)
|
(7)
|
58
|
10
|
10
|
Bevespi
|
10
|
-
|
(5)
|
10
|
-
|
2
|
10
|
4
|
8
|
12
|
8
|
5
|
Breztri
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
(74)
|
(73)
|
Others
|
128
|
(14)
|
(12)
|
101
|
(21)
|
(23)
|
102
|
1
|
(1)
|
135
|
33
|
38
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,283
|
(6)
|
(6)
|
1,252
|
(2)
|
(2)
|
1,319
|
5
|
6
|
1,537
|
17
|
17
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
363
|
(7)
|
(8)
|
393
|
8
|
8
|
374
|
(5)
|
(4)
|
353
|
(6)
|
(6)
|
Synagis*
|
53
|
(79)
|
(79)
|
96
|
81
|
81
|
146
|
52
|
53
|
63
|
(57)
|
(57)
|
Losec/Prilosec*
|
76
|
27
|
26
|
68
|
(11)
|
(10)
|
73
|
8
|
9
|
46
|
(38)
|
(38)
|
Seroquel XR/IR*
|
37
|
(34)
|
(33)
|
32
|
(14)
|
(10)
|
82
|
n/m
|
n/m
|
40
|
(50)
|
(49)
|
Others
|
47
|
(65)
|
(64)
|
52
|
11
|
11
|
56
|
8
|
-
|
151
|
n/m
|
n/m
|
Total other medicines
|
576
|
(35)
|
(36)
|
641
|
11
|
12
|
731
|
14
|
14
|
653
|
(11)
|
(10)
|
Total Product Sales
|
5,465
|
(5)
|
(6)
|
5,718
|
5
|
5
|
6,132
|
7
|
8
|
6,250
|
2
|
3
|
|
|
YTD 2020
|
YTD 2019
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
$m
|
||
Initial Collaboration Revenue
|
Crestor (Spain)
|
-
|
-
|
-
|
61
|
Ongoing Collaboration Revenue
|
Lynparza: regulatory
milestones
|
135
|
60
|
60
|
140
|
Lynparza: sales
milestones
|
-
|
200
|
450
|
250
|
|
Lynparza/selumetinib: option
payments
|
-
|
-
|
100
|
400
|
|
Crestor (Spain)
|
-
|
-
|
39
|
-
|
|
Enhertu: profit
share
|
63
|
-
|
-
|
-
|
|
Roxadustat: profit share
|
19
|
-
|
-
|
-
|
|
Royalty income
|
47
|
42
|
62
|
49
|
|
|
Other Collaboration Revenue
|
64
|
103
|
108
|
141
|
Total
|
328
|
405
|
819
|
1,041
|
|
YTD 2020
|
YTD 2019
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
$m
|
|
Hypertension medicines (ex-US, India and Japan)
|
350
|
-
|
-
|
-
|
Monetisation of an asset previously licensed
|
120
|
-
|
-
|
-
|
Brazikumab licence termination funding
|
51
|
-
|
-
|
-
|
Inderal, Tenormin, Seloken and Omepral (Japan)
|
51
|
-
|
-
|
-
|
Synagis (US)
|
-
|
515
|
515
|
-
|
Losec (ex-China, Japan, US and
Mexico)
|
-
|
243
|
243
|
-
|
Seroquel and Seroquel XR (US,
Canada, Europe and Russia)
|
-
|
-
|
213
|
-
|
Arimidex and
Casodex
(various
countries)
|
-
|
-
|
181
|
-
|
Nexium (Europe) and
Vimovo
(ex-US)
|
-
|
-
|
-
|
728
|
Seroquel
|
-
|
-
|
-
|
527
|
Legal settlement
|
-
|
-
|
-
|
346
|
Atacand
|
-
|
-
|
-
|
210
|
Anaesthetics
|
-
|
-
|
-
|
172
|
Alvesco, Omnaris and Zetonna
|
-
|
-
|
-
|
139
|
Other
|
316
|
283
|
389
|
405
|
Total
|
888
|
1,041
|
1,541
|
2,527
|
Announcement of
full year and fourth quarter results
|
11
February 2021
|
|
Announcement of
first quarter results
|
30
April 2021
|
|
Announcement of
half year and second quarter results
|
29 July
2021
|
|
Announcement of
year to date and third quarter results
|
12
November 2021
|
|
|
||
Dividends are
normally be paid as follows:
|
||
First
interim:
|
announced
with the half year and fourth quarter results and paid in
March
|
|
Second
interim:
|
announced
with full year and fourth quarter results and paid in
March
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|